Methods for treating conditions associated with MASP-2 dependent complement activation
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
C07K-016/40
A61K-039/00
출원번호
US-0441827
(2012-04-06)
등록번호
US-8951522
(2015-02-10)
발명자
/ 주소
Demopulos, Gregory A.
Dudler, Thomas
Schwaeble, Hans-Wilhelm
출원인 / 주소
University of Leicester
대리인 / 주소
Quinton, Tineka J.
인용정보
피인용 횟수 :
0인용 특허 :
32
초록▼
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
대표청구항▼
1. A method of inhibiting MASP-2-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), comprising administering to the subject a composition comprising an amount of a monoclonal MASP-2 inhibitory antibody, or antigen-binding fragment thereof, that spe
1. A method of inhibiting MASP-2-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), comprising administering to the subject a composition comprising an amount of a monoclonal MASP-2 inhibitory antibody, or antigen-binding fragment thereof, that specifically binds to a portion of SEQ ID NO:6 and selectively inhibits MASP-2-dependent complement activation without substantially inhibiting the C1q-dependent complement pathway. 2. The method of claim 1, wherein the composition increases the survival of red blood cells in the subject. 3. The method of claim 1, wherein the subject exhibits one or more symptoms selected from the group consisting of (i) below normal levels of hemoglobin, (ii) below normal levels of platelets; (iii) above normal levels of reticulocytes, and (iv) above normal levels of bilirubin. 4. The method of claim 1, wherein the subject has previously undergone, or is currently undergoing, treatment with an anti-C5 antibody or antigen binding fragment thereof that inhibits cleavage of complement protein C5. 5. The method of claim 1, wherein the method further comprises administering to the subject an anti-C5 antibody or antigen binding fragment thereof that inhibits cleavage of complement protein C5. 6. The method of claim 5, wherein the anti-C5 antibody or antigen binding fragment thereof is humanized. 7. The method of claim 6, wherein the anti-C5 antibody is eculizumab. 8. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is a recombinant antibody. 9. The method of claim 1, wherein the composition is administered subcutaneously, intra-muscularly, intra-arterially, intravenously, or as an inhalant. 10. The method of claim 1, wherein the composition is administered subcutaneously. 11. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is an antibody having reduced effector function. 12. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is a chimeric antibody. 13. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is a humanized antibody. 14. The method of claim 1, wherein the monoclonal antibody or antigen-binding fragment thereof is a human antibody.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (32)
Baker Brenda ; Bennett C. Frank ; Anderson Kevin P., Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Ladner Robert C. (Ijamsville MD) Guterman Sonia K. (Belmont MA) Roberts Bruce L. (Milford MA) Markland William (Milford MA) Ley Arthur C. (Newton MA) Kent Rachel B. (Boxborough MA), Directed evolution of novel binding proteins.
Queen Cary L. (Los Altos CA) Co Man Sung (Cupertino CA) Schneider William P. (Mountain View CA) Landolfi Nicholas F. (Milpitas CA) Coelingh Kathleen L. (San Francisco CA) Selick Harold E. (Belmont CA, Humanized immunoglobulins.
Yamada Yoshihiko (Silver Spring MD) Sasaki Makoto (Beppu MD JPX) Kleinman Hynda K. (Bethesda MD) Martin George R. (Bethesda MD), Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides.
Yagi Kunio (Aichi-ken JPX) Noda Hitoshi (Aichi-ken JPX) Ohishi Nobuko (Gifu JPX) Kurono Masayasu (Mie-ken JPX), Liposome for entrapping gene, liposomal preparation and process for the manufacture of the preparation.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Goldenberg Milton D. (11837 Gainsborough Rd. Potomac MD 20854), Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.